A multicenter and longitudinal study with a larger sample size is required to confirm the effects of the HSPA8 SNP on hepatic and CVD pathogenesis in NAFLD patients. This evidence concerns the gene HSPA8 and metabolic dysfunction-associated steatotic liver disease.